Everest Medicines (HKG:1952) said the first patient was dosed in a clinical trial of its mRNA cancer vaccine EVM16 at Peking University Cancer Hospital,
The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in advanced or recurrent solid tumors.
The clinical trial of EVM16 is being conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, according to a Thursday news release.
Shares of the biopharmaceutical company soared 18% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。